```html

Hereditary Hemochromatosis – A Complete Patient Guide

Overview

Hereditary hemochromatosis (HH) is a genetic disorder that causes the body to absorb too much iron from the diet. The excess iron is stored primarily in the liver, heart, pancreas, joints, and skin, leading to organ damage over time if it is not treated.

Who it affects: The condition is most common in people of Northern European descent, especially those of Celtic (Irish, Scottish, Welsh) ancestry. Although both sexes carry the gene, men usually develop clinical disease earlier because women lose iron through menstruation and pregnancy.

Prevalence: Approximately 1 in 200–300 people of European ancestry are homozygous for the most common mutation (C282Y) in the HFE gene—roughly 0.3–0.5 % of the population. However, only about 10–15 % of those with the genotype develop iron overload symptoms (Mayo Clinic, 2023).

Symptoms

Symptoms develop slowly and may be absent for decades. The classic “triad” of cirrhosis, diabetes mellitus, and skin hyperpigmentation is now recognised as only one possible presentation. Below is a comprehensive list:

• Fatigue & weakness – often the first vague complaint.
• Joint pain – especially in the second and third metacarpophalangeal (MCP) joints, knees, hips, and shoulders.
• Abdominal pain – due to liver enlargement or early cirrhosis.
• Loss of libido or erectile dysfunction – related to hormonal disturbances.
• Skin hyperpigmentation – bronze or grayish tinge, most noticeable on sun‑exposed areas.
Metabolic complications
• Type 2 diabetes mellitus (“bronze diabetes”).
• Hypothyroidism or adrenal insufficiency (rare).
• Cardiac manifestations – cardiomyopathy, arrhythmias, or congestive heart failure.
• Hepatic signs – hepatomegaly, elevated liver enzymes, progressing to fibrosis or cirrhosis; in rare cases, hepatocellular carcinoma.
• Endocrine & reproductive – early menopause in women, infertility, or testicular atrophy.
• Neurologic/psychiatric – depression, memory problems, or “brain fog,” sometimes linked to iron deposition in the basal ganglia.

Causes and Risk Factors

Genetic basis

HH is an autosomal recessive disorder. The two most common pathogenic variants in the HFE gene are:

• C282Y (c.845G>A) – accounts for ~85 % of clinically significant cases.
• H63D (c.187C>G) – usually milder; disease most often occurs when combined with C282Y (compound heterozygosity).

Other rarer genes (e.g., TFR2, SLC40A1, HJV, HAMP) cause “non‑HFE” hereditary hemochromatosis, often presenting in childhood or early adulthood.

Risk factors

• Genotype – homozygous C282Y or compound heterozygous C282Y/H63D confer the highest risk.
• Gender – men develop symptoms 10–15 years earlier and more often than women.
• Age – iron accumulation is progressive; clinical disease typically appears after age 40 in men and after menopause in women.
• Alcohol use – synergistic liver injury; even moderate drinking increases cirrhosis risk.
• Co‑existing liver disease – hepatitis B/C, non‑alcoholic fatty liver disease (NAFLD) accelerate fibrosis.

Diagnosis

Because early disease is silent, targeted screening of at‑risk individuals (first‑degree relatives of a confirmed case) is recommended.

Initial laboratory evaluation

• Serum transferrin saturation (TS) – calculated as (serum iron ÷ total iron‑binding capacity) × 100. Values > 45 % are abnormal; > 60 % strongly suggest HH.
• Serum ferritin – reflects body iron stores. Levels > 300 ng/mL in men and > 200 ng/mL in women warrant further work‑up, but ferritin can be elevated with inflammation, so interpretation must be contextual.

Genetic testing

Confirmation is achieved by testing for the common HFE mutations. Testing is most useful when:

• TS > 45 % and ferritin is elevated.
• There is a family history of HH or iron‑related complications.

Imaging and liver assessment

• Magnetic resonance imaging (MRI) with T2* or R2* sequences – non‑invasive quantification of hepatic iron concentration; valuable for monitoring treatment response.
• Ultrasound or elastography (FibroScan) – assess liver stiffness and rule out cirrhosis.
• Liver biopsy – rarely needed now; reserved for cases where imaging is equivocal or when other liver disease must be excluded.

Additional tests

If organ involvement is suspected, targeted investigations are performed:

• Cardiac MRI or echocardiogram for cardiomyopathy.
• Oral glucose tolerance test or HbA1c for diabetes.
• Endocrine panel (thyroid, cortisol) if symptoms suggest hormonal dysfunction.

Treatment Options

The goal of therapy is to remove excess iron and prevent organ damage while maintaining adequate iron for normal physiologic needs.

Phlebotomy (Therapeutic Venesection)

• Standard of care – removal of 450–500 mL of whole blood weekly until ferritin falls below 50 ng/mL (often 6–12 weeks).
• Maintenance phase – once target ferritin is achieved, phlebotomy is performed every 2–4 months to keep ferritin between 50–100 ng/mL.
• Contraindications – anemia, severe cardiac disease, or poor venous access; in such cases, alternative methods are considered.

Iron‑Chelation Therapy

Used when phlebotomy is not feasible (e.g., anemia, heart failure).

• Deferasirox (Exjade, Jadenu) – oral, taken daily; monitor renal and hepatic function.
• Deferoxamine (Desferal) – subcutaneous infusion over 8–12 hours, 5–7 days/week; usually reserved for severe cases.

Lifestyle & Dietary Modifications

• Limit iron‑rich foods – red meat, organ meats, fortified cereals.
• Avoid vitamin C megadoses (≥1000 mg/day) with meals, as it enhances iron absorption.
• Reduce alcohol consumption – ≤ 1 drink/day for women, ≤ 2 drinks/day for men, or complete abstinence if liver disease exists.
• Avoid raw shellfish – risk of Vibrio vulnificus infection is higher in iron‑overloaded individuals.

Management of Complications

Specific organ damage is treated according to standard guidelines:

• Diabetes – lifestyle + oral agents/insulin as needed (American Diabetes Association).
• Cirrhosis – surveillance for hepatocellular carcinoma (ultrasound every 6 months) and screening for varices.
• Heart failure – guideline‑directed medical therapy; consider cardiac MRI to assess iron load.

Living with Hereditary Hemochromatosis

Daily Management Tips

• Track phlebotomy appointments – use a calendar or health‑app reminder.
• Monitor iron studies regularly – ferritin and TS every 3–6 months during induction, then every 6–12 months during maintenance.
• Stay hydrated – especially after phlebotomy, to replace plasma volume.
• Maintain a balanced diet – focus on fruits, vegetables, whole grains, and low‑iron protein sources (poultry, fish).
• Exercise regularly – moderate aerobic activity improves cardiovascular health and can mitigate fatigue.
• Family screening – encourage first‑degree relatives to get genetic testing even if asymptomatic.

Psychosocial considerations

Living with a chronic genetic condition can cause anxiety about inheritance and future health. Access to genetic counseling, support groups (e.g., Hemochromatosis Society of America), and mental‑health resources is encouraged.

Prevention

Because HH is genetic, primary prevention is not possible. However, secondary prevention—reducing the risk of complications—is achievable:

1. Early detection through family screening and periodic iron studies.
2. Prompt initiation of phlebotomy when iron overload is identified.
3. Adopt lifestyle measures (low‑iron diet, limited alcohol, safe food handling).
4. Vaccinate against hepatitis A and B to protect an already vulnerable liver.

Complications

If untreated, excess iron causes irreversible organ damage. Major complications include:

• Cirrhosis and liver cancer – risk of hepatocellular carcinoma is 2–5 % in untreated patients with cirrhosis.
• Diabetes mellitus – iron deposits damage pancreatic β‑cells.
• Cardiomyopathy – restrictive or dilated patterns; may lead to arrhythmias or sudden cardiac death.
• Arthropathy – chronic joint pain mimicking osteoarthritis; may require joint replacement.
• Endocrine dysfunction – hypothyroidism, hypogonadism, adrenal insufficiency.
• Infections – especially with Vibrio vulnificus from raw oysters; iron‑overloaded tissue provides a fertile environment for certain bacteria.

When to Seek Emergency Care

---

Sources: Mayo Clinic; Cleveland Clinic; American College of Gastroenterology guidelines (2022); National Institutes of Health (NIH) – Genetics Home Reference; World Health Organization (WHO) – Iron Overload Disorders; CDC – Vibrio vulnificus recommendations.

```